BACKGROUND: Anthroposophic medications (AMED) are prescribed in 56 countries. OBJECTIVE: To study clinical outcomes in @entity1 prescribed AMED for @entity102 . DESIGN: Prospective cohort study. SETTING: 110 medical practices in Germany. @entity1 : 665 consecutive outpatients aged 1-71 years, prescribed AMED for mental, respiratory, musculoskeletal, neurological, genitourinary, and other @entity102 . MAIN OUTCOMES: Disease and Symptom Scores (physicians' and @entity1 ' assessment, 0-10) and SF-36. RESULTS: During the first six months, an average of 1.5 AMED per @entity1 was used, in total 652 different AMED. Origin of AMED was mineral (8.0% of 652 AMED), botanical (39.0%), zoological (7.2%), chemically defined (13.0%), and mixed (33.0%). From baseline to six-month-follow-up, all outcomes improved significantly: Disease Score improved by mean 3.15 points (95% confidence interval 2.97-3.34, p < 0.001), Symptom Score by 2.43 points (2.23-2.63, p < 0.001), SF-36 Physical Component Summary by 3.04 points (2.16-3.91, p < 0.001), and SF-36 Mental Component Summary by 5.75 points (4.59-6.92, p < 0.001). All improvements were maintained at 12-month follow-up. Improvements were similar in adult @entity1 and @entity1 , in @entity1 , and in @entity1 not using adjunctive therapies. CONCLUSION: Outpatients using AMED for @entity102 had long-term reduction of disease severity and improvement of quality of life.

Outcome of anthroposophic medication therapy in XXXX : a 12-month prospective cohort study.

@entity1 :: ('9606', 'Species') :: ['women', 'children', 'patients', 'patient', 'PARTICIPANTS', 'men'] @entity102 :: ('MESH:D002908', 'Disease') :: ['chronic disease', 'chronic diseases']
@entity102 :: (MESH:D002908,Disease) :: ['chronic disease']
